BRPI0818672B8 - composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas - Google Patents

composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas

Info

Publication number
BRPI0818672B8
BRPI0818672B8 BRPI0818672A BRPI0818672A BRPI0818672B8 BR PI0818672 B8 BRPI0818672 B8 BR PI0818672B8 BR PI0818672 A BRPI0818672 A BR PI0818672A BR PI0818672 A BRPI0818672 A BR PI0818672A BR PI0818672 B8 BRPI0818672 B8 BR PI0818672B8
Authority
BR
Brazil
Prior art keywords
compositions
pharmaceutical compositions
deoxytetrahydrouridines
fluor
compounds
Prior art date
Application number
BRPI0818672A
Other languages
English (en)
Portuguese (pt)
Inventor
Duvall Bridget
V Ferraris Dana
S Hamilton Gregory
Lapidus Rena
Tsukamoto Takashi
Original Assignee
Eisai Inc
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818672(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Inc, Otsuka Pharma Co Ltd filed Critical Eisai Inc
Publication of BRPI0818672A2 publication Critical patent/BRPI0818672A2/pt
Publication of BRPI0818672B1 publication Critical patent/BRPI0818672B1/pt
Publication of BRPI0818672B8 publication Critical patent/BRPI0818672B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0818672A 2007-10-16 2008-10-16 composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas BRPI0818672B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16
US60/980,397 2007-10-16
PCT/US2008/080163 WO2009052287A1 (en) 2007-10-16 2008-10-16 2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Publications (3)

Publication Number Publication Date
BRPI0818672A2 BRPI0818672A2 (pt) 2015-04-14
BRPI0818672B1 BRPI0818672B1 (pt) 2020-10-20
BRPI0818672B8 true BRPI0818672B8 (pt) 2021-05-25

Family

ID=40251685

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818672A BRPI0818672B8 (pt) 2007-10-16 2008-10-16 composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas

Country Status (39)

Country Link
US (4) US8268800B2 (enExample)
EP (2) EP2207786B1 (enExample)
JP (2) JP5496899B2 (enExample)
KR (1) KR101543049B1 (enExample)
CN (1) CN101827856B (enExample)
AT (1) ATE548374T1 (enExample)
BR (1) BRPI0818672B8 (enExample)
CA (1) CA2702274C (enExample)
CO (1) CO6270330A2 (enExample)
CR (1) CR11427A (enExample)
CY (3) CY1112781T1 (enExample)
DK (1) DK2207786T3 (enExample)
EA (1) EA018757B1 (enExample)
EC (1) ECSP10010095A (enExample)
ES (2) ES2616566T3 (enExample)
FI (2) FIC20230040I1 (enExample)
FR (2) FR23C1051I2 (enExample)
GT (1) GT201000088A (enExample)
HR (1) HRP20120419T1 (enExample)
HU (2) HUS2300045I1 (enExample)
IL (1) IL204732A (enExample)
JO (1) JO2778B1 (enExample)
LT (2) LTPA2023539I1 (enExample)
ME (1) ME00997B (enExample)
MX (1) MX2010004109A (enExample)
MY (1) MY147970A (enExample)
NI (1) NI201000055A (enExample)
NL (2) NL301257I2 (enExample)
NO (2) NO2023048I1 (enExample)
NZ (1) NZ584229A (enExample)
PL (1) PL2207786T3 (enExample)
PT (1) PT2207786E (enExample)
RS (1) RS52323B (enExample)
SA (1) SA08290661B1 (enExample)
SI (1) SI2207786T1 (enExample)
TW (1) TWI445539B (enExample)
UA (1) UA99476C2 (enExample)
WO (1) WO2009052287A1 (enExample)
ZA (1) ZA201002178B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
NZ623495A (en) 2008-05-15 2015-08-28 Celgene Corp Oral formulations of cytidine analogs and methods of use thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
JO3262B1 (ar) * 2009-04-06 2018-09-16 Otsuka Pharma Co Ltd توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
ES2628609T3 (es) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
WO2010118006A1 (en) 2009-04-06 2010-10-14 Eisai Inc. (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
DE202012013382U1 (de) 2011-09-16 2016-08-23 Gilead Pharmasset Llc Zusammensetzungen zur Behandlung von HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP3650013A1 (en) 2013-01-31 2020-05-13 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
KR102272773B1 (ko) * 2013-10-29 2021-07-02 오츠카 세이야쿠 가부시키가이샤 2'-데옥시-2',2'-디플루오로테트라하이드로우리딘의 합성 경로
MX385778B (es) 2014-04-04 2025-03-18 Del Mar Pharmaceuticals Uso de dianhidrogalactitol y análogos o derivados del mismo para tratar cáncer de células no pequeñas del pulmón y cáncer de ovario.
KR20170042598A (ko) 2014-08-22 2017-04-19 셀진 코포레이션 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
MX393043B (es) * 2015-12-03 2025-03-24 Epidestiny Inc Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos
WO2017158396A1 (en) * 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
KR20200118827A (ko) 2018-02-02 2020-10-16 마베릭스 온콜로지, 잉크. 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트
EP3844477A4 (en) * 2018-08-28 2023-01-04 Essenlix Corporation IMPROVING THE ACCURACY OF A DOSAGE
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
US12448624B2 (en) 2018-10-19 2025-10-21 Interoligo Corporation Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
KR102280330B1 (ko) * 2018-10-19 2021-07-21 인터올리고 주식회사 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
BR112022006523A2 (pt) * 2019-10-08 2022-06-28 Otsuka Pharma Co Ltd 2'-desóxi-2',2'-difluorotetraidrouridinas com alta pureza e métodos para produção da mesma
PH12022552250A1 (en) * 2020-02-25 2023-11-13 Otsuka Pharma Co Ltd Combination decitabine and cedazuridine solid oral dosage forms
EP4313069A4 (en) * 2021-03-26 2024-12-18 The Cleveland Clinic Foundation TREATMENT OF RNA VIRUS INFECTION WITH A CYTIDINE INDEAMINASE INHIBITOR
WO2022254457A1 (en) * 2021-05-29 2022-12-08 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
JP2024539267A (ja) 2021-10-19 2024-10-28 アキラバイオ， インコーポレイテッド ２’－デオキシシチジンアナログを含む組成物、ならびに鎌状赤血球症、サラセミアおよびがんを処置するためのその使用
WO2023076332A1 (en) * 2021-11-01 2023-05-04 St. John's University Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
EP4580635A1 (en) 2022-08-31 2025-07-09 Taiho Pharmaceutical Co., Ltd. Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
AU583801B2 (en) 1983-10-26 1989-05-11 Sheldon B. Greer Method and materials for sensitizing neoplastic tissue to radiation
EP0184365B1 (en) * 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
CA2086233C (en) 1991-04-23 1995-10-17 Wendy Oglevee-O'donovan In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) * 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
EP0641352B1 (en) * 1993-02-23 1997-06-04 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
AU6081294A (en) * 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
WO1996026743A1 (en) * 1995-03-01 1996-09-06 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) * 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
US6933287B1 (en) * 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
PT1156827E (pt) * 1999-03-01 2007-01-31 Halogenetics Inc Utilização de composições compreendendo cidc como radiossensibilizadores no tratamento de doenças neoplásicas
MXPA02002088A (es) 1999-08-26 2003-09-22 Aortech Internat Plc Mejoras en relacion al posicionamiento del cateter.
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
US7125983B2 (en) * 2000-11-29 2006-10-24 Mitsui Chemicals, Inc. L-nucleic acid derivatives and process for the synthesis thereof
ATE290882T1 (de) * 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
WO2002094844A2 (en) 2001-05-18 2002-11-28 Rakesh Kumar Antiviral nucleosides
JP2005508885A (ja) * 2001-07-31 2005-04-07 ザ ステイト オブ オレゴン， アクティング バイ アンド スルー ザ ステイト ボード オブ ハイヤー エデュケイション オン ビハーフ オブ ザ ユニバーシティー オブ オレゴン Ｄｎａメチル化の阻害剤
JP2005522443A (ja) 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
CA2499036A1 (en) 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
WO2004041203A2 (en) 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN101076536A (zh) 2004-07-30 2007-11-21 药华医药股份有限公司 β－核苷的立体选择性合成
CN101076535A (zh) 2004-12-08 2007-11-21 西科尔公司 二氟核苷及其制备方法
WO2008085611A2 (en) 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
WO2010118006A1 (en) * 2009-04-06 2010-10-14 Eisai Inc. (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer
ES2628609T3 (es) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
JO3262B1 (ar) * 2009-04-06 2018-09-16 Otsuka Pharma Co Ltd توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان

Also Published As

Publication number Publication date
DK2207786T3 (da) 2012-06-18
AU2008312435B2 (en) 2014-04-17
FIC20230039I1 (fi) 2023-12-22
HUS2300045I1 (hu) 2024-01-28
WO2009052287A1 (en) 2009-04-23
CN101827856B (zh) 2013-02-06
NL301257I2 (nl) 2025-11-06
PT2207786E (pt) 2012-05-28
CR11427A (es) 2010-08-16
FIC20230040I1 (fi) 2023-12-22
HUS2300044I1 (hu) 2024-01-28
UA99476C2 (en) 2012-08-27
US9567363B2 (en) 2017-02-14
SI2207786T1 (sl) 2012-10-30
LTPA2023538I1 (enExample) 2024-02-26
TWI445539B (zh) 2014-07-21
US20140186335A1 (en) 2014-07-03
JO2778B1 (en) 2014-03-15
KR101543049B1 (ko) 2015-08-07
BRPI0818672B1 (pt) 2020-10-20
ME00997B (me) 2012-10-20
ES2384011T3 (es) 2012-06-28
CY2023029I1 (el) 2024-02-16
EA018757B1 (ru) 2013-10-30
EP2207786A1 (en) 2010-07-21
CY2023028I1 (el) 2024-02-16
GT201000088A (es) 2012-03-13
ECSP10010095A (es) 2010-07-30
HK1146410A1 (en) 2011-06-03
EP2447272B1 (en) 2017-02-01
ZA201002178B (en) 2011-05-25
JP2011500713A (ja) 2011-01-06
CA2702274C (en) 2015-12-29
CO6270330A2 (es) 2011-04-20
FR23C1051I1 (fr) 2024-01-26
FR23C1052I2 (fr) 2025-02-07
ATE548374T1 (de) 2012-03-15
JP2014177455A (ja) 2014-09-25
JP5496899B2 (ja) 2014-05-21
NO2023047I1 (no) 2023-12-21
LTPA2023539I1 (enExample) 2024-02-26
EA201000642A1 (ru) 2010-10-29
ES2616566T3 (es) 2017-06-13
AU2008312435A1 (en) 2009-04-23
US8268800B2 (en) 2012-09-18
PL2207786T3 (pl) 2012-09-28
FR23C1051I2 (fr) 2025-02-07
US20150210730A1 (en) 2015-07-30
IL204732A0 (en) 2010-11-30
NL301256I2 (nl) 2024-01-11
MX2010004109A (es) 2010-08-10
BRPI0818672A2 (pt) 2015-04-14
LTC2207786I2 (enExample) 2025-09-10
MY147970A (en) 2013-02-28
FR23C1052I1 (fr) 2024-01-26
AU2008312435A8 (en) 2014-07-24
NO2023048I1 (en) 2023-12-21
CY1112781T1 (el) 2016-02-10
EP2447272A1 (en) 2012-05-02
EP2207786B1 (en) 2012-03-07
CN101827856A (zh) 2010-09-08
KR20100091978A (ko) 2010-08-19
IL204732A (en) 2013-07-31
HRP20120419T1 (hr) 2012-07-31
JP5859588B2 (ja) 2016-02-10
US8951987B2 (en) 2015-02-10
US20090137521A1 (en) 2009-05-28
US8618075B2 (en) 2013-12-31
SA08290661B1 (ar) 2012-06-10
NI201000055A (es) 2010-08-13
NZ584229A (en) 2012-06-29
US20120289475A1 (en) 2012-11-15
RS52323B (sr) 2012-12-31
NL301256I1 (enExample) 2024-01-03
TW200924786A (en) 2009-06-16
CA2702274A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
BRPI0818672B8 (pt) composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
BRPI0815708A8 (pt) composto derivado de benzilbenzeno como inibidor de sglt, composição farmacêutica, e, uso de um composto
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
ECSP109968A (es) Depsipéptidos cíclicos
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
CR10381A (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
CL2008003712A1 (es) Compuestos derivados de tiadiazololoxifenilamidina o tiazoliloxifenilamidina; su procedimiento de preparacion; uso y procedimiento para combatir microorganismos no deseados; agente que comprende a dichos compuestos; compuestos intermediarios; y su procedimiento de preparacion.
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
GT200600144A (es) 1h-quinazolin-2,4-dionas
ECSP099679A (es) Nuevos compuestos y sus usos 707
BRPI0605926A2 (pt) ciclopentanos substituìdos ou ciclopentanonas como agentes terapêuticos
ECSP109874A (es) Nuevos compuestos 892
BRPI0620985B1 (pt) composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina
ECSP045271A (es) Derivados de quinolina
DE602007007653D1 (de) Neue morphinderivate
PA8668901A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como antiinflamatorios

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: OTSUKA PHARMACEUTICAL CO., LTD (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF